Name: Metastatic Breast Cancer Market Size Share Growth & Forecast 2023-2030
Creator: DataM Intelligence
Published: Thu Nov 02 2023 12:13:40 GMT+0530 (India Standard Time)
License: https://www.datamintelligence.com/terms-conditions
Keywords: Metastatic Breast Cancer Market

Metastatic Breast Cancer Market Size Share Growth & Forecast 2023-2030

Metastatic Breast Cancer Market Size, Share, Industry, Forecast and Outlook (2023-2030)

<h2>Global Metastatic Breast Cancer Market is Segmented By Treatment Type (Chemotherapy, Immunotherapy, Hormone Therapy, Radiation Therapy), By Route of Administration (Oral, Parenteral), By End User (Hospitals, Specialty Clinics, Cancer Research Centers, Others),&nbsp;and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030</h2>

<h3>Metastatic Breast Cancer Market Overview</h3>

<blockquote>
Global Metastatic Breast Cancer market reached US$ YY&nbsp;million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
</blockquote>

Metastatic breast cancer, also known as stage IV, occurs when breast cancer cells have spread to other parts of the body, such as the bones, lungs, brain, or liver. This process of cancer spreading is called metastasis, which happens when cancer cells break away from the original tumor in the breast and travel to other parts of the body through the bloodstream or the lymphatic system.&nbsp;

Systemic medications, such as chemotherapy, hormonal therapy, targeted therapies, and immunotherapy, are usually used to treat metastatic breast cancer throughout the entire body. In some cases, local treatments, such as surgery or radiation, may also be recommended to target a specific part of the body.

<h3>Metastatic Breast Cancer Market Scope</h3>

<table cellspacing="0" style="border-collapse:collapse; width:624px">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #8eaadb; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			YY%
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Market Size Available for Years
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2021-2030
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Estimation Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2023-2030
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Revenue Units
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$ Mn)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Treatment Type, Route of Administration, End User
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America, and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter&rsquo;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

For more details on this report <a href="https://www.datamintelligence.com/download-sample/metastatic-breast-cancer-market" target="_blank">Request for Sample</a>

<h2>&nbsp;</h2>

<h3>Metastatic Breast Cancer Market Dynamics: Drivers &amp; Restraints</h3>

Growing Prevalence

The growing prevalence of metastatic breast cancer is expected to boost the global market growth during the forecast period. For instance, according to the American Society of Clinical Oncology (ASCO), in the United States, around 6% of females have metastatic breast cancer when they are first analyzed.&nbsp;

Breast cancer is the second most typical reason for death from cancer in females in the United States. Also, it is assessed that about 43,700 individuals (43,170 females and 530 males) casualties from this disease will transpire in the United States in 2023. Moreover, according to the American Medical Association, around 20 to 30 percent of early-stage breast cancer evolves as metastatic or stage IV, the most fierce and devastating state of breast cancer, usually ignored until it evolves as challenging to handle.

Furthermore, growing awareness and research activites among other factors are also expected to contribute to the global market growth during the forecast period.

Absence of Efficacious Therapies

However, the absence of efficacious therapies and treatment-related adverse outcomes could restrict the growth of the metastatic breast cancer market during the forecast period. Furthermore, the lack of awareness and professionals are among the additional factors hampering the global market growth..

<h3>Metastatic Breast Cancer Market Segmentation</h3>

The global metastatic breast cancer market is segmented based on treatment type, route of administration, end user and region.

Immunotherapy Treatment Type is Expected to Dominate Market

Owing to the increasing positive outcomes from clinical investigations and product approvals is expected to boost the segment growth during the forecast period, dominating the global market. For instance, in August 2023, the final analysis of the phase III TROPiCS-02 study published by the Lancet revealed that the antibody-drug conjugate sacituzumab govitecan-hziy persisted to present exceptional advantage for individuals with hormone receptor&ndash;positive, HER2-negative metastatic breast cancer when corresponded with classic chemotherapy.&nbsp;

Moreover, in February 2023, Gilead Sciences, Inc. obtained the U.S. Food and Drug Administration (FDA) authorization for its Trodelvy (sacituzumab govitecan-hziy) to treat adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH&ndash;) breast cancer who have obtained endocrine-based treatment and at short two other systemic treatments in the metastatic setting.

<h3>Global Metastatic Breast Cancer Geographical Share</h3>

North America is Expected to Dominate the Global Market 

Owing to the presence of key market players in North America holding major shares of the global market through distinct market strategies including mergers, acquisitions, expansions, and securing funding, the region is expected to dominate the global market during the forecast period.&nbsp;

For instance, in March 2023, Pfizer Inc and Seagen formed a final coalition contract following which Pfizer Inc intends to acquire Seagen, a global biotechnology corporation involved in the discovery, development, and commercialization of innovative cancer therapies, for $229 in cash per Seagen share for a whole enterprise worth of $43 billion.&nbsp;

Moreover, in October 2022, PIC Therapeutics, Inc., a Massachusetts headquartered biopharmaceutical corporation committed to designing life-changing therapies for individuals with cancer, secured a $35 million Series A financing conducted by OrbiMed.

<h3>COVID-19 Impact Analysis</h3>

Due to the COVID-19 pandemic, there was a significant decrease in cancer diagnosis among breast, colon, and rectal cancers in the first few months, according to a study published in JAMA Network Open. Another study published in the European Journal of Epidemiology reported an overall decrease of approximately 37.3% in diagnostic tests during the pandemic, resulting in 27% fewer cancer diagnoses. This decrease in cancer diagnosis has lowered the demand for cancer therapies.

<h3>Key Developments</h3>

<ul>
	<li>In March 2023, Verzenio (abemaciclib) received an expanded indication from the FDA for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at high risk of recurrence when used in combination with endocrine therapy (ET).&nbsp;</li>
	<li>In July 2023, according to initial data from a phase 2 trial being conducted in Europe, Ixabepilone (Ixempra) provided clinical benefit to patients with metastatic breast cancer who had been selected for treatment with the DRP-IXEMPRA companion diagnostic (CDx) candidate.&nbsp;</li>
	<li>In August 2023, the FDA and Eagle Pharmaceuticals reached a consensus in a Type C meeting to determine the next steps for the development of EA-114, a novel formulation of fulvestrant (Faslodex) and an estrogen receptor antagonist used in the treatment of postmenopausal women with breast cancer.</li>
</ul>

<h3>Metastatic Breast Cancer Market Companies</h3>

The major global players in the market include Hoffmann-La Roche, Pfizer Inc, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline Plc, AstraZeneca, Amgen Inc., Merck and Co. Inc. and Novartis AG among others.

Why Purchase the Report?

<ul>
	<li>To visualize the global metastatic breast cancer market segmentation based on treatment type, route of administration, end user and region as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analyzing trends and co-development.&nbsp;</li>
	<li>Excel data sheet with numerous data points of metastatic breast cancer market-level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping available as excel consisting of key products of all the major players.</li>
</ul>

The global metastatic breast cancer market report would provide approximately 61 tables, 58 figures and 184 pages.

<h3>Target Audience 2023</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Treatment Type</li>
		<li>Snippet by Route of Administration</li>
		<li>Snippet by End User</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Growing Prevalence</li>
				<li>XX</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>Absence of Efficacious Therapies</li>
				<li>XX</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Force Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Unmet Needs</li>
		<li>Patent Analysis</li>
		<li>Pipeline Analysis</li>
		<li>Epidemiology&nbsp;</li>
		<li>SWOT Analysis</li>
		<li>DMI Opinion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID</li>
			<li>Scenario During COVID</li>
			<li>Scenario Post COVID</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Treatment Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Attractiveness Index, By Treatment Type</li>
		</ol>
		</li>
		<li>Chemotherapy*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Immunotherapy</li>
		<li>Hormone Therapy</li>
		<li>Radiation Therapy</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Route of Administration</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Attractiveness Index, By Route of Administration</li>
		</ol>
		</li>
		<li>Oral*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Parenteral</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By End User</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Attractiveness Index, By End User</li>
		</ol>
		</li>
		<li>Hospitals*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Specialty Clinics</li>
		<li>Cancer Research Centers</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>Hoffmann-La Roche*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Pfizer Inc</li>
		<li>Bristol-Myers Squibb, Inc.</li>
		<li>Boehringer Ingelheim GmbH</li>
		<li>Eli Lilly and Company</li>
		<li>GlaxoSmithKline Plc</li>
		<li>AstraZeneca, Inc.</li>
		<li>Amgen Inc.</li>
		<li>Novartis AG&nbsp;</li>
		<li>Merck and Co. Inc.&nbsp;(*LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

&nbsp;

<ul>
</ul>

<h3>List of Tables</h3>

Table 1 Global Metastatic Breast Cancer Market Value, By Treatment Type, 2022, 2026 &amp; 2030 (US$ Million)

Table 2 Global Metastatic Breast Cancer Market Value, By Route of Administration, 2022, 2026 &amp; 2030 (US$ Million)

Table 3 Global Metastatic Breast Cancer Market Value, By End User, 2022, 2026 &amp; 2030 (US$ Million)

Table 4 Global Metastatic Breast Cancer Market Value, By Region, 2022, 2026 &amp; 2030 (US$ Million)

Table 5 Global Metastatic Breast Cancer Market Value, By Treatment Type, 2022, 2026 &amp; 2030 (US$ Million)

Table 6 Global Metastatic Breast Cancer Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 7 Global Metastatic Breast Cancer Market Value, By Route of Administration, 2022, 2026 &amp; 2030 (US$ Million)

Table 8 Global Metastatic Breast Cancer Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Metastatic Breast Cancer Market Value, By End User, 2022, 2026 &amp; 2030 (US$ Million)

Table 10 Global Metastatic Breast Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 11 Global Metastatic Breast Cancer Market Value, By Region, 2022, 2026 &amp; 2030 (US$ Million)

Table 12 Global Metastatic Breast Cancer Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Metastatic Breast Cancer Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 14 North America Metastatic Breast Cancer Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Metastatic Breast Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 16 North America Metastatic Breast Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Metastatic Breast Cancer Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 18 South America Metastatic Breast Cancer Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Metastatic Breast Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 20 South America Metastatic Breast Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Metastatic Breast Cancer Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 22 Europe Metastatic Breast Cancer Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Metastatic Breast Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 24 Europe Metastatic Breast Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Metastatic Breast Cancer Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Metastatic Breast Cancer Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Metastatic Breast Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Metastatic Breast Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East &amp; Africa Metastatic Breast Cancer Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 30 Middle East &amp; Africa Metastatic Breast Cancer Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East &amp; Africa Metastatic Breast Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 32 Hoffmann-La Roche: Overview

Table 33 Hoffmann-La Roche: Product Portfolio

Table 34 Hoffmann-La Roche: Key Developments

Table 35 Pfizer Inc: Overview

Table 36 Pfizer Inc: Product Portfolio

Table 37 Pfizer Inc: Key Developments

Table 38 Bristol-Myers Squibb, Inc.: Overview

Table 39 Bristol-Myers Squibb, Inc.: Product Portfolio

Table 40 Bristol-Myers Squibb, Inc.: Key Developments

Table 41 Boehringer Ingelheim GmbH: Overview

Table 42 Boehringer Ingelheim GmbH: Product Portfolio

Table 43 Boehringer Ingelheim GmbH: Key Developments

Table 44 Eli Lilly and Company: Overview

Table 45 Eli Lilly and Company: Product Portfolio

Table 46 Eli Lilly and Company: Key Developments

Table 47 GlaxoSmithKline Plc: Overview

Table 48 GlaxoSmithKline Plc: Product Portfolio

Table 49 GlaxoSmithKline Plc: Key Developments

Table 50 AstraZeneca, Inc.: Overview

Table 51 AstraZeneca, Inc.: Product Portfolio

Table 52 AstraZeneca, Inc.: Key Developments

Table 53 Amgen Inc.: Overview

Table 54 Amgen Inc.: Product Portfolio

Table 55 Amgen Inc.: Key Developments

Table 56 Novartis AG: Overview

Table 57 Novartis AG: Product Portfolio

Table 58 Novartis AG: Key Developments

Table 59 Merck and Co. Inc.: Overview

Table 60 Merck and Co. Inc.: Product Portfolio

Table 61 Merck and Co. Inc.: Key Developments

<h3>List of Figures</h3>

Figure 1 Global Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 2 Global Metastatic Breast Cancer Market Share, By Treatment Type, 2022 &amp; 2030 (%)

Figure 3 Global Metastatic Breast Cancer Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 4 Global Metastatic Breast Cancer Market Share, By End User, 2022 &amp; 2030 (%)

Figure 5 Global Metastatic Breast Cancer Market Share, By Region, 2022 &amp; 2030 (%)

Figure 6 Global Metastatic Breast Cancer Market Y-o-Y Growth, By Treatment Type, 2022-2030 (%)

Figure 7 Chemotherapy Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 8 Immunotherapy Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 9 Hormone Therapy Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 10 Radiation Therapy Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 11 Global Metastatic Breast Cancer Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 12 Oral Route of Administration in Global Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 13 Parenteral Route of Administration in Global Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 14 Global Metastatic Breast Cancer Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 15 Hospitals End User in Global Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 16 Specialty Clinics End User in Global Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 17 Cancer Research Centers End User in Global Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 18 Others End User in Global Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 19 Global Metastatic Breast Cancer Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 20 North America Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 21 Asia-Pacific Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 22 Europe Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 23 South America Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 24 Middle East and Africa Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 25 North America Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 26 North America Metastatic Breast Cancer Market Share, By Treatment Type, 2022 &amp; 2030 (%)

Figure 27 North America Metastatic Breast Cancer Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 28 North America Metastatic Breast Cancer Market Share, By End User, 2022 &amp; 2030 (%)

Figure 29 North America Metastatic Breast Cancer Market Share, By Country, 2022 &amp; 2030 (%)

Figure 30 South America Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 31 South America Metastatic Breast Cancer Market Share, By Treatment Type, 2022 &amp; 2030 (%)

Figure 32 South America Metastatic Breast Cancer Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 33 South America Metastatic Breast Cancer Market Share, By End User, 2022 &amp; 2030 (%)

Figure 34 South America Metastatic Breast Cancer Market Share, By Country, 2022 &amp; 2030 (%)

Figure 35 Europe Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 36 Europe Metastatic Breast Cancer Market Share, By Treatment Type, 2022 &amp; 2030 (%)

Figure 37 Europe Metastatic Breast Cancer Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 38 Europe Metastatic Breast Cancer Market Share, By End User, 2022 &amp; 2030 (%)

Figure 39 Europe Metastatic Breast Cancer Market Share, By Country, 2022 &amp; 2030 (%)

Figure 40 Asia-Pacific Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 41 Asia-Pacific Metastatic Breast Cancer Market Share, By Treatment Type, 2022 &amp; 2030 (%)

Figure 42 Asia-Pacific Metastatic Breast Cancer Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 43 Asia-Pacific Metastatic Breast Cancer Market Share, By End User, 2022 &amp; 2030 (%)

Figure 44 Asia-Pacific Metastatic Breast Cancer Market Share, By Country, 2022 &amp; 2030 (%)

Figure 45 Middle East &amp; Africa Metastatic Breast Cancer Market Value, 2021-2030 (US$ Million)

Figure 46 Middle East &amp; Africa Metastatic Breast Cancer Market Share, By Treatment Type, 2022 &amp; 2030 (%)

Figure 47 Middle East &amp; Africa Metastatic Breast Cancer Market Share, By Route of Administration, 2022 &amp; 2030 (%)

Figure 48 Middle East &amp; Africa Metastatic Breast Cancer Market Share, By End User, 2022 &amp; 2030 (%)

Figure 49 Hoffmann-La Roche: Financials

Figure 50 Pfizer Inc: Financials

Figure 51 Bristol-Myers Squibb, Inc.: Financials

Figure 52 Boehringer Ingelheim GmbH: Financials

Figure 53 Eli Lilly and Company: Financials

Figure 54 GlaxoSmithKline Plc: Financials

Figure 55 AstraZeneca, Inc.: Financials

Figure 56 Amgen Inc.: Financials

Figure 57 Novartis AG: Financials

Figure 58 Merck and Co. Inc.: Financials

Metastatic Breast Cancer Market Size, Share, Industry, Forecast and Outlook (2023-2030)

Metastatic Prostate Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 February 28

Starting from

Metastatic Colorectal Cancer Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2024 November 07

Starting from

Breast Cancer Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 June 25

Starting from

Triple Negative Breast Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 October 22

Starting from

HER2-Negative Breast Cancer – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2022 August 11

Starting from